Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets ROME III criteria for functional dyspepsia (FD)~* Patient has a normal esophagogastroduodenoscopy (EGD) either during the Screening Period or within 2 years of the Screening Visit~* Patients who EITHER:~  1. Have not used a proton pump inhibitor (PPI) within 4 weeks of the Screening Visit, OR~ 2. Have used a PPI at a stable dose for at least 4 weeks prior to the Screening Visit;~* Patient meets symptom severity criteria in the Pretreatment Period~* Patient is fluent and literate in Dutch, French, or English~Exclusion Criteria:~* Patient meets criteria for gastroesophageal reflux disease (GERD, stable regimen of PPIs acceptable), constipation, diarrhea, lower abdominal pain, or gastroparesis~* Patient has a history of inflammatory bowel disease, chronic pancreatitis, small intestinal bacterial overgrowth, celiac disease, lactose intolerance, polycystic kidney disease, interstitial cystitis, or scleroderma~* Any significant neurological disease or a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable; complete remission of other cancers for 5 years or longer is also acceptable)~* History of active alcoholism or drug addiction within 12 months prior to the Screening Visit~* Hospitalized for a psychiatric condition or has made a suicide attempt during the two years before the Screening Visit~* Any organic or structural disease that can cause abdominal pain or discomfort

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IW-9179 (Type: EXPERIMENTAL): Oral IW-9179 taken daily for two weeks
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo taken daily for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).